To view this email as a web page, click here

Today's Rundown

Featured Story

AstraZeneca aims to get COVID-19 therapy into clinic in 2 months

AstraZeneca is planning to start a phase 1 clinical trial of a COVID-19 antibody therapy within two months. The commitment follows the signing of a deal that grants AstraZeneca an exclusive license to six anti-SARS-CoV-2 antibodies identified by researchers at Vanderbilt University.

read more

Top Stories

Lundbeck plotting up to 160 R&D job cuts as it rebuilds pipeline

Lundbeck wants to rebuild its pipeline and sharpen focus on neuroscience in the coming years, and this will mean swinging the ax across its research organization.

read more

After 11 years, Sanofi kicks backs the rights to unwanted gene therapies to Oxford Biomedica

Oxford Biomedica is currently most well known for its work on COVID-19 vaccines and its tie-up with AstraZeneca, but a much older deal sits with French Big Pharma Sanofi.

read more

Roche pens $2B biobucks pact with Innovent Biologics for bispecific and cell therapies

Roche is licensing out part of its cancer platform to Chinese biotech Innovent Biologics.

read more

BIO: Orchard CEO Gaspar on the company's 2020 pivot

In 2019, it was all systems go for Orchard Therapeutics. The company had pulled off a $200 million IPO, picked up GlaxoSmithKline’s stable of rare disease gene therapies and planned to break ground on a $90 million manufacturing site in California. Now, under the wing of a new CEO, the company has reined it in.

read more

Lilly starts second COVID-19 antibody test with partner Junshi Biosciences, eyes combo trials

In just over a week Eli Lilly has gone from having nothing in the clinic to not one but now two antibody drugs targeting SARS-CoV-2 as it also eyes combining both, and more besides, for a more potent affect.

read more

Lycia Therapeutics uncloaks with $50M to tackle protein degradation in a new way

Having spent nearly a decade at NASH-focused NGM Bio, Aetna Wun Trombley knew it would take "something very special" to lure her away. That opportunity was Lycia Therapeutics, which is launching out of Versant Ventures with $50 million and technology from Stanford University to develop drugs that exploit protein degradation.

read more

Personalized cancer test maker ArcherDX files $100M IPO

An international pandemic notwithstanding, the cancer-focused genomic testing company ArcherDX is forging ahead with a $100 million IPO, following a busy month of pharma partnerships and FDA announcements.

read more

Researchers probe new drug strategies for keeping pancreatic cancer at bay

Inhibiting a protein called Slug could halt the spread of pancreatic cancer cells, a Sanford Burnham team reported, while scientists at the University of Cincinnati are using a nanodrug to improve the targeting of chemotherapy to pancreatic tumors. Both approaches aim to improve the prognosis for a cancer that's often not detected until it has spread.

read more

Enrollment Showcase

A Credential for the Future of Health Care

Position yourself as a precision medicine leader with the online graduate program in precision medicine. Learn the latest in genomic technologies and precision medicine therapies from experts in research and implementation. Join the future of health care with the flexibility and convenience of an online program.

Resources

Whitepaper: Pandemic respiratory vaccine clinical trials: a departure from business as usual

Download this whitepaper to learn more about the success factors that are required to keep a pandemic respiratory vaccine trial running at optimal speed and efficiency.

Whitepaper: Brand Revitalization with RP Scherer Softgel Solutions for Analgesics

In a series of innovation sessions, Catalent RP Scherer softgel capsules were quickly identified as the ideal solution to drive incremental growth. Learn more.

Whitepaper: 7 Keys to Success in Europe

White paper describing 7 keys to success for any biopharma company that is entering (or thinking about entering) Europe.

Whitepaper: Rapid BYOD Build Timelines

This white paper covers a Phase III case study; BYOD advantages and misconceptions; and regulatory, copyright, and equivalency considerations.

Whitepaper: Keep Your GI Trials Moving During COVID-19

Learn how GI specific data capture solutions can support virtual and hybrid trials during COVID-19.

Whitepaper: The Evolution and Importance of Biomedical Ontologies for Scientific Literature

Dive into the history of biomedical classification and how these systems have evolved to address new technology and use cases.

Whitepaper: Pandemic respiratory vaccine clinical trials: a departure from business as usual

Download this whitepaper to learn more about the success factors that are required to keep a pandemic respiratory vaccine trial running at optimal speed and efficiency.

Case Study: Establishing Parameters for Success

Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study.

Fact Sheet: Forecasting to Optimize Clinical Trial Supply Management

Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study.

eBook: Expecting the Unexpected: Strategies for Efficient Clinical Supply Management and Forecasting

Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study.

Case Study: Precision Analytics for Product Launch and Growth

Pharma launch teams spend significant resources on data and analytics with limited ROI. Read this case study to learn how a Life Sciences company identified two times more patients best suited for therapy, using Clarify’s deep and longitudinal patient and HCP insights. 

Podcast: Developing residual HCPs ELISA assay for biopharmaceutical products

Listen to our brand-new Frontage Laboratories podcast where you’ll take home tips for developing residual host cell proteins ELISA assay for biopharmaceutical products using commercial kits.

Virtual Event: Cardiac Safety London Online

Join us for a day of discovery as global experts in Cardiology, Pharmacology and Diabetes discuss state of the art methods in early phase clinical research.

Report: Decentralized Trials - Where Does the Industry Stand?

Patient-facing digital technologies are playing an important role in clinical trials for new drugs and medical devices, to the point where conducting virtual trials is becoming mainstream. But terms like remote trials, direct-to-patient trials, hybrid trials, decentralized trials, and more all add to the confusion of what makes a trial "virtual."

Whitepaper: Why Your Business Needs An Effective Cloud Strategy To Survive Now

Businesses must maintain pre-pandemic levels of productivity with smaller IT budgets. Learn why an effective Cloud Strategy is imperative for success in these unprecedented times.

Events